Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.41
QDEL's Cash to Debt is ranked lower than
63% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. QDEL: 1.41 )
Ranked among companies with meaningful Cash to Debt only.
QDEL' s 10-Year Cash to Debt Range
Min: 0.09  Med: 1.87 Max: 13.76
Current: 1.41
0.09
13.76
Equity to Asset 0.54
QDEL's Equity to Asset is ranked lower than
62% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. QDEL: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
QDEL' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.79 Max: 0.88
Current: 0.54
0.52
0.88
F-Score: 6
Z-Score: 3.41
M-Score: -4.35
WACC vs ROIC
7.86%
0.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 0.83
QDEL's Operating margin (%) is ranked higher than
52% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.26 vs. QDEL: 0.83 )
Ranked among companies with meaningful Operating margin (%) only.
QDEL' s 10-Year Operating margin (%) Range
Min: -13.49  Med: 3.10 Max: 31.99
Current: 0.83
-13.49
31.99
Net-margin (%) -1.79
QDEL's Net-margin (%) is ranked higher than
50% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. QDEL: -1.79 )
Ranked among companies with meaningful Net-margin (%) only.
QDEL' s 10-Year Net-margin (%) Range
Min: -10.03  Med: 3.21 Max: 21.25
Current: -1.79
-10.03
21.25
ROE (%) -1.54
QDEL's ROE (%) is ranked lower than
51% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. QDEL: -1.54 )
Ranked among companies with meaningful ROE (%) only.
QDEL' s 10-Year ROE (%) Range
Min: -11.35  Med: 3.27 Max: 26.77
Current: -1.54
-11.35
26.77
ROA (%) -0.96
QDEL's ROA (%) is ranked higher than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.89 vs. QDEL: -0.96 )
Ranked among companies with meaningful ROA (%) only.
QDEL' s 10-Year ROA (%) Range
Min: -8.68  Med: 2.66 Max: 21.27
Current: -0.96
-8.68
21.27
ROC (Joel Greenblatt) (%) 2.04
QDEL's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.36 vs. QDEL: 2.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QDEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33.25  Med: 13.95 Max: 145.36
Current: 2.04
-33.25
145.36
Revenue Growth (3Y)(%) 3.60
QDEL's Revenue Growth (3Y)(%) is ranked lower than
59% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. QDEL: 3.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
QDEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.1  Med: 5.70 Max: 20.6
Current: 3.6
-5.1
20.6
EBITDA Growth (3Y)(%) -15.90
QDEL's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. QDEL: -15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QDEL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -58.2  Med: 10.40 Max: 242
Current: -15.9
-58.2
242
» QDEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

QDEL Guru Trades in Q2 2014

Mario Gabelli 601,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q3 2014

QDEL Guru Trades in Q3 2014

Paul Tudor Jones 200,000 sh (New)
Mario Gabelli 600,000 sh (-0.17%)
» More
Q4 2014

QDEL Guru Trades in Q4 2014

Steven Cohen 417,200 sh (New)
Mario Gabelli 600,000 sh (unchged)
Paul Tudor Jones 152,400 sh (-23.80%)
» More
Q1 2015

QDEL Guru Trades in Q1 2015

Joel Greenblatt 14,247 sh (New)
Mario Gabelli 600,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 46.08
QDEL's Forward P/E is ranked lower than
84% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. QDEL: 46.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.04
QDEL's P/B is ranked higher than
54% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.58 vs. QDEL: 3.04 )
Ranked among companies with meaningful P/B only.
QDEL' s 10-Year P/B Range
Min: 1.5  Med: 3.57 Max: 6.72
Current: 3.04
1.5
6.72
P/S 3.67
QDEL's P/S is ranked lower than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. QDEL: 3.67 )
Ranked among companies with meaningful P/S only.
QDEL' s 10-Year P/S Range
Min: 1.45  Med: 3.97 Max: 6.27
Current: 3.67
1.45
6.27
PFCF 25.00
QDEL's PFCF is ranked higher than
54% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.48 vs. QDEL: 25.00 )
Ranked among companies with meaningful PFCF only.
QDEL' s 10-Year PFCF Range
Min: 5.91  Med: 25.37 Max: 393
Current: 25
5.91
393
POCF 17.73
QDEL's POCF is ranked higher than
58% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.03 vs. QDEL: 17.73 )
Ranked among companies with meaningful POCF only.
QDEL' s 10-Year POCF Range
Min: 5.35  Med: 19.72 Max: 481.67
Current: 17.73
5.35
481.67
EV-to-EBIT 395.04
QDEL's EV-to-EBIT is ranked lower than
99% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.73 vs. QDEL: 395.04 )
Ranked among companies with meaningful EV-to-EBIT only.
QDEL' s 10-Year EV-to-EBIT Range
Min: -201.7  Med: 23.20 Max: 590.6
Current: 395.04
-201.7
590.6
Shiller P/E 106.48
QDEL's Shiller P/E is ranked lower than
92% of the 53 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.91 vs. QDEL: 106.48 )
Ranked among companies with meaningful Shiller P/E only.
QDEL' s 10-Year Shiller P/E Range
Min: 22.56  Med: 61.00 Max: 1297
Current: 106.48
22.56
1297
Current Ratio 7.61
QDEL's Current Ratio is ranked higher than
86% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. QDEL: 7.61 )
Ranked among companies with meaningful Current Ratio only.
QDEL' s 10-Year Current Ratio Range
Min: 1.64  Med: 4.09 Max: 8.08
Current: 7.61
1.64
8.08
Quick Ratio 6.92
QDEL's Quick Ratio is ranked higher than
84% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. QDEL: 6.92 )
Ranked among companies with meaningful Quick Ratio only.
QDEL' s 10-Year Quick Ratio Range
Min: 1.12  Med: 3.11 Max: 7.26
Current: 6.92
1.12
7.26
Days Inventory 115.78
QDEL's Days Inventory is ranked lower than
65% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. QDEL: 115.78 )
Ranked among companies with meaningful Days Inventory only.
QDEL' s 10-Year Days Inventory Range
Min: 70.68  Med: 86.14 Max: 128.92
Current: 115.78
70.68
128.92
Days Sales Outstanding 28.55
QDEL's Days Sales Outstanding is ranked higher than
90% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.45 vs. QDEL: 28.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
QDEL' s 10-Year Days Sales Outstanding Range
Min: 21.59  Med: 68.89 Max: 95.31
Current: 28.55
21.59
95.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 126.29
QDEL's Price/Net Cash is ranked lower than
97% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.89 vs. QDEL: 126.29 )
Ranked among companies with meaningful Price/Net Cash only.
QDEL' s 10-Year Price/Net Cash Range
Min: 7.53  Med: 20.89 Max: 189.2
Current: 126.29
7.53
189.2
Price/Net Current Asset Value 11.80
QDEL's Price/Net Current Asset Value is ranked lower than
69% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.30 vs. QDEL: 11.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QDEL' s 10-Year Price/Net Current Asset Value Range
Min: 3.45  Med: 11.76 Max: 272.83
Current: 11.8
3.45
272.83
Price/Tangible Book 6.45
QDEL's Price/Tangible Book is ranked lower than
65% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.26 vs. QDEL: 6.45 )
Ranked among companies with meaningful Price/Tangible Book only.
QDEL' s 10-Year Price/Tangible Book Range
Min: 1.14  Med: 4.86 Max: 15.44
Current: 6.45
1.14
15.44
Price/Projected FCF 2.20
QDEL's Price/Projected FCF is ranked lower than
55% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. QDEL: 2.20 )
Ranked among companies with meaningful Price/Projected FCF only.
QDEL' s 10-Year Price/Projected FCF Range
Min: 0.98  Med: 2.73 Max: 11.48
Current: 2.2
0.98
11.48
Price/Median PS Value 0.94
QDEL's Price/Median PS Value is ranked higher than
59% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. QDEL: 0.94 )
Ranked among companies with meaningful Price/Median PS Value only.
QDEL' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 0.79 Max: 1.53
Current: 0.94
0.26
1.53
Earnings Yield (Greenblatt) (%) 0.22
QDEL's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. QDEL: 0.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QDEL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 3.40 Max: 17.5
Current: 0.22
0.2
17.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:QL1.Germany,
Quidel Corp was incorporated in the State of Delaware. It commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions for applications mainly in infectious diseases and reproductive and women's health. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Its diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers, by addressing varying requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. Internationally, the Company sells and markets mainly in Japan, Europe, and the Middle East through exclusive distributor arrangements. During 2012, the Company continued to invest in several key areas: support for clinical research and expanding its communications through promotional campaigns, peer-reviewed technical publications, professional shows and exhibits, symposia, medical education and support of health economics and outcomes research. In 2012, it had manufacturing operations in San Diego and Santa Clara, California and Athens, Ohio Customers for IVD products are mainly centralized laboratories and physician offices and other decentralized non-institutional settings. Its objective is to build a broader-based diagnostic company, with products in market segments that are growing to realize increased shareholder value. The Company competes with several large pharmaceutical and diversified healthcare companies. The testing, manufacture and commercialization of its products are subjected to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies.
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Quidel Receives FDA Clearance for Its AmpliVue Trichomonas Assay: A Hand-Held Molecular Diagnostic T Mar 17 2015 
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014 
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parain Oct 15 2014 
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus Oct 15 2014 
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014 Oct 15 2014 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 

More From Other Websites
QUIDEL CORP /DE/ Financials Jul 29 2015
10-Q for Quidel Corp. Jul 25 2015
Edited Transcript of QDEL earnings conference call or presentation 22-Jul-15 9:00pm GMT Jul 23 2015
QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report Jul 23 2015
Quidel reports 2Q loss Jul 22 2015
Quidel reports 2Q loss Jul 22 2015
Quidel Corp Earnings Call scheduled for 5:00 pm ET today Jul 22 2015
Quidel Reports Second Quarter 2015 Financial Results Jul 22 2015
QUIDEL CORP /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 22 2015
Quidel Reports Second Quarter 2015 Financial Results Jul 22 2015
Q2 2015 Quidel Corp Earnings Release - After Market Close Jul 22 2015
Quidel to Hold Second Quarter 2015 Financial Results Conference Call on July 22, 2015 Jul 07 2015
Quidel to Hold Second Quarter 2015 Financial Results Conference Call on July 22, 2015 Jul 07 2015
Quidel Receives FDA Clearance for Its New Solana(TM) Molecular System and Solana(TM) Molecular Assay... Jun 23 2015
Quidel Receives FDA Clearance for Its New Solana(TM) Molecular System and Solana(TM) Molecular Assay... Jun 23 2015
QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Jun 18 2015
QUIDEL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 05 2015
Quidel to Present at the Goldman Sachs 36th Annual Global Healthcare Conference May 28 2015
Quidel to Present at the Goldman Sachs 36th Annual Global Healthcare Conference May 28 2015
QUIDEL CORP /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK